Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia.

Abstract

Severe persistent pulmonary hypertension of the newborn (PPHN) remains a significant cause of neonatal morbidity and mortality with limited effective treatment options. We present the first case of a neonate with PPHN treated concurrently with inhaled nitric oxide (iNO) and intravenous prostacyclin (PGI2). He ultimately was diagnosed with alveolar-capillary dysplasia, a rare and fatal cause of pulmonary hypertension. However, his partial response to treatment demonstrates a possible role for combined therapy with iNO and PGI2 in infants with severe PPHN.

• Authors: T A Parker, D D Ivy, J P Kinsella, F Torielli, S Z Ruyle, E H Thilo, S H Abman
• Journal: American journal of respiratory and critical care medicine (Am J Respir Crit Care Med) Vol. 155 Issue 2 Pg. 743-6 (Feb 1997) ISSN: 1073-449X [Print] United States
• PMID: 9032222 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antihypertensive Agents
• Nitric Oxide
• Epoprostenol

Topics

• Antihypertensive Agents (therapeutic use)
• Echocardiography
• Epoprostenol (administration & dosage)
• Fatal Outcome
• Humans
• Hypertension, Pulmonary (drug therapy, etiology, physiopathology)
• Infant, Newborn
• Infant, Newborn, Diseases (drug therapy, physiopathology)
• Male
• Nitric Oxide (administration & dosage)
• Pulmonary Artery (abnormalities)
• Pulmonary Veins (abnormalities)